Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available in oral (delayed-release tablets, suspension) and intravenous (IV) formulations.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD symptoms.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been used; individualize titration based on patient need.
* **GERD/Short-term Relief:** 20 mg orally once daily for up to 4 weeks.
## Pediatric Dosing
* **GERD (Age 5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* ≥40 kg: 40 mg once daily.
* *Note:* Use in patients <5 years is not recommended due to limited data.
## Dose Adjustments
* **Hepatic Impairment:** Reduce dose in severe hepatic impairment (Child-Pugh C). Maximum dose often cited as 20 mg daily or 40 mg every other day; monitor closely.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions (with IV).
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous lupus erythematosus, bone fractures (long-term/high-dose).
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of ketoconazole, atazanavir, and mycophenolate mofetil.
* **CYP450:** Generally has a lower potential for CYP enzyme interactions compared to omeprazole, but use caution with medications requiring acidic gastric pH for absorption.
* **Methotrexate:** PPIs may increase serum levels of methotrexate; temporary discontinuation may be required during high-dose methotrexate therapy.
## Monitoring
* **Baseline:** Magnesium levels (if long-term therapy or concurrent with diuretics/digoxin).
* **Ongoing:** Monitor for symptom resolution. Assess need for ongoing therapy; deprescribe if not clinically indicated to minimize long-term risks.
## Clinical Pearls
* **IV Administration:** IV pantoprazole may be administered as a slow infusion (15 minutes) or a rapid injection (2 minutes).
* **Bioavailability:** IV to oral conversion is 1:1.
* **Administration:** Oral delayed-release tablets should be swallowed whole; do not crush or chew.
* **Hypersecretory states:** Dosing is highly variable and depends on individual secretory status; consult institutional protocols or specialist guidelines for titration.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and local prescribing protocols change frequently. Always verify the most current prescribing information via institutional resources, FDA/EMA package inserts, or clinical decision support tools before initiating therapy.
